Noninferiority study shows no increased risk for acute MI with two-dose HepB-CpG vaccine versus three-dose HepB-alum vaccine<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, April 1, 2022 (HealthDay News) — The rate of type 1 acute myocardial infarction (MI) is not increased with receipt of the two-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) versus the three-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine), according to a study published online March 25 in the Journal of the American Medical Association<\/em>.<\/p>\n Katia Bruxvoort, Ph.D., from the University of Alabama at Birmingham, and colleagues conducted a prospective cohort noninferiority study to compare the rate of acute MI between recipients of the HepB-CpG vaccine (31,183 individuals) and HepB-alum vaccine (38,442 individuals). Participants were followed for 13 months after the index dose.<\/p>\n After inverse probability of treatment weighting, the characteristics were well-balanced between the vaccine groups. The researchers identified 52 type 1 acute MI events among recipients of HepB-CpG vaccine and 71 type 1 acute MI events among recipients of HepB-alum vaccine, for rates of 1.67 and 1.86 per 1,000 person-years, respectively (absolute rate difference, \u00e2\u0088\u00920.19; adjusted hazard ratio, 0.92, which was below the noninferiority margin).<\/p>\n “Further research is needed to determine if individuals would be more likely to initiate a shorter two-dose series than a longer three-dose series, as well as to address vaccine hesitancy and other barriers to hepatitis B vaccine uptake among adults,” the authors write.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Dynavax Technologies, which manufactures HEPLISAV-B and funded the study.<\/p>\n